Chemexpress(SH:688131) Zheng Quan Zhi Xing·2025-03-27 16:25Meeting Overview - The fourth meeting of the fourth Supervisory Board of Shanghai Haoyuan Pharmaceutical Co., Ltd. was held on March 26, 2025, in accordance with legal regulations [1] - The meeting was convened by the chairman of the Supervisory Board, Mr. Zhang Yucheng, with all three supervisors present, ensuring the legality and validity of the resolutions [1] Resolutions Passed - The Supervisory Board approved the 2024 work report of the Supervisory Board, with a unanimous vote of 100% in favor [2] - The 2024 annual report and summary were approved, confirming compliance with legal and regulatory requirements, also with a unanimous vote of 100% in favor [2] - The financial settlement report for 2024 was approved, with a unanimous vote of 100% in favor [2] - The financial budget report for 2025 was approved, with a unanimous vote of 100% in favor [2] - The reappointment of Rongcheng Accounting Firm as the auditing institution for 2025 was approved, with a unanimous vote of 100% in favor [3] - The special report on the use of raised funds for 2024 was approved, confirming compliance with relevant regulations, with a unanimous vote of 100% in favor [4] - The proposal to postpone certain fundraising project investments was approved, with a unanimous vote of 100% in favor [5] - The internal control evaluation report for 2024 was approved, with a unanimous vote of 100% in favor [6] - The proposal for the 2025 supervisor remuneration was submitted for the annual shareholders' meeting due to all supervisors abstaining from voting [6] - The expected daily related transactions for 2025 were approved, with a unanimous vote of 100% in favor [6] - The proposal for the company and its subsidiaries to apply for a comprehensive credit limit from banks and provide guarantees was approved, with a unanimous vote of 100% in favor [7] - The proposal for asset impairment provision was approved, with a unanimous vote of 100% in favor [7] - The profit distribution plan for 2024 was approved, with a unanimous vote of 100% in favor [8] - The mid-term dividend arrangement for 2025 was approved, with a unanimous vote of 100% in favor [8] - The annual evaluation report for the "Quality Improvement and Efficiency Enhancement Return" special action plan for 2024 was approved, with a unanimous vote of 100% in favor [9] - The special action plan for 2025 was approved, with a unanimous vote of 100% in favor [9] - The performance commitment realization and compensation plan for Yaoyuan Pharmaceutical Chemical (Shanghai) Co., Ltd. was approved, with a unanimous vote of 100% in favor [10] - The proposal to invalidate certain unvested restricted stock from the 2022 incentive plan was approved, with a unanimous vote of 100% in favor [11] - The conditions for the third vesting period of the initial grant of the 2022 restricted stock incentive plan were confirmed, with a unanimous vote of 100% in favor [12]